Citations

Clear

4610 citation(s) found for "Lu, Brian".

Global Variations in Practices After Bariatric and Metabolic Surgery; the PARTNER study
Clyde, Danielle , Grant, Callum, Canales, Juan Andres Aguiar, Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Goodpaster, Kasey , Hopkins, George, Jatana, Anita , Kothari, Shanu N. , Kow, Lillian, Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Ratcliffe, Denise , Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Voon, Kelvin , Lamb, Peter , Mahawar, Kamal , Grant, Callum, Canales, Juan Andres Aguiar, Cameron, David, Copăescu, Cătălin , Clare, Ken , Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Hazebroek, Eric J. , Husain, Farah Anwari , Joyce, Brian, Kermansaravi, Mohammad , Miras, Alexander Dimitri , Moizé, Violeta , Neto, Manoel Galvão , Peterli, Ralph , Sakran, Nasser , Salminen, Paulina , Singhal, Rishi , Stenberg, Erik , Tahrani, Abd A. , Vilallonga, Ramón , Welbourn, Richard , Zerrweck, Carlos , Moussa, Osama , Byrne, James Patrick , Parmar, Chetan D. , Ghanem, Omar M. , Robertson, Andrew G. , Yang, Wah

Mayo Clinic

No container title available | August 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6779565/v1 Get It

Abstract Background: With over 1 billion individuals affected globally, obesity and obesity related diseases is now a leading cause of death. Metabolic and bariatric surgery (MBS) has emerged as a cornerstone intervention for severe obesity and its associated comorbidities. Despite its efficacy, postoperative care and follow-up after MBS remains highly variable worldwide. Objective: The PARTNER study aimed to evaluate global clinical practices in the postoperative management following MBS by surveying multidisciplinary healthcare professionals . Methods: This study was an international online survey conducted between October 2024 and January 2025. A multidisciplinary team developed the questionnaire based on existing literature and international guidelines. The survey assessed five domains: follow-up care, postoperative treatment, dietary management, patient support, and measurement of surgical outcomes. Responses were analysed descriptively. Results: A total of 262 responses were received from 62 countries. Most respondents were bariatric surgeons (72.1%) working in public healthcare systems (73.3%). While 78.7% reported conducting three-month postoperative reviews, only 23.7% offered indefinite follow-up. Hybrid models of care (virtual and in-person) were common (56.9%). VTE prophylaxis and postoperative PPI use were recommended by 64.1% and 84.3% respectively. Nearly all respondents (98.1%) provided dietary advice, with protein and micronutrient supplementation widely endorsed. Only 56.1% routinely referred patients for psychological follow-up. Definitions of surgical success and failure varied widely, with inconsistent objective outcome measures. Conclusion: The PARTNER study reveals significant international variation in postoperative management practices following MBS. These findings underscore the need for more standardized, evidence-based guidelines to improve long-term outcomes and equity of care worldwide.
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis
Rangarajan, Hemalatha G. , Satwani, Prakash , Chen, Min , Wudhikarn, Kitsada , Marks, David I. , Kelly, Matthew S. , Farhadfar, Nosha , Prestidge, Tim , Hossain, Nasheed , Liu, Hongtao , Hashmi, Shahrukh K. , Modi, Dipenkumar , Winestone, Lena E. , Boghdadly, Zeinab El , Chemaly, Roy F. , Dandoy, Christopher E. , Hill, Joshua A. , Huppler, Anna R. , Riches, Marcie , Herr, Megan M. , Martens, Michael J , Kelkar, Amar H , Ringden, Olov , Friend, Brian D , Kelly, Matthew S , Prestidge, Tim , Hossain, Nasheed M , Liu, Hongtao , Hashmi, Shahrukh K , Modi, Dipenkumar , Winestone, Lena E , Murthy, Hemant S , Perales, Miguel-Angel , Chemaly, Roy F , Dandoy, Christopher E , Hill, Joshua A , Huppler, Anna R , Auletta, Jeffery J , Martens, Michael J. , John, Samuel, Fabrizio, Vanessa A , Hsieh, Emily M. , Doherty, Erin , Ringdén, Olle , Murthy, Hemant S. , Perales, Miguel‐Angel , Auletta, Jeffery J.

Mayo Clinic

Blood Advances | July 30, 2025 | Volume: 9 | Issue: 21 | Pages: 5489-5500

10.1182/bloodadvances.2025016149 | PMID 40737539 Get It

Abstract Tisagenlecleucel (tisa-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory precursor B-cell acute lymphoblastic leukemia (R/R B-ALL). We report infectious complications for 100 days (D100) following tisa-cel therapy in 471 pediatric and young adults (median age 13.8 years) with R/R B-ALL reported from September 2017 to June 2022. By D100, 137 (29%) patients had an infectious event, with an infection density of 0.542 per 100 person-days at risk. D100 cumulative incidences of bacterial, viral, and fungal infections were 14.1%, 11.6%, and 1.3%, corresponding to infection density scores of 0.296, 0.213, and 0.033 per 100 person-days at risk, respectively. In a multivariable analysis, receipt of ≥3 lines of therapy before tisa-cel (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.13-3.08; P = .015), any-grade cytokine release syndrome (HR, 1.78; 95% CI, 1.17-2.71; P = .007), and lack of neutrophil recovery (HR, 2.63; 95% CI, 1.47-4.69; P = .001) were associated with an increased risk for any infection. Similar associations were observed for bacterial infections, with the addition of younger age as an adverse risk (<6 vs 6-15 years; HR, 2.38; 95% CI, 1.23-4.61; P = .01). Risk factors for viral infections included increasing age (1-year increase; HR, 1.05; 95% CI, 1.01-1.09; P = .016), prior history of any infection (HR, 2.76, 95% CI, 1.40-5.46; P = .004), and prior hematopoietic cell transplant (HR, 2.10; 95% CI, 1.18-3.71; P = .011). D100 infection-related mortality (IRM) rate was low at 0.2% (95% CI, 0.0-0.8). In this multicenter real-world study, we observed a high incidence of infectious complications but a low IRM following tisa-cel for R/R B-ALL.
Breast Cancer Method of Detection: Frequently Asked Questions
Bahl, Manisha , Aminololama‐Shakeri, Shadi , Chen, L, Chikarmane, Sona A. , Dontchos, Brian N. , Lampen-Sachar, Katharine , Langman, Eun L. , Rosen, Eric L. , Rossi, Joanna , Ghate, Sujata V. , Dontchos, Brian N , Ojeda-Fournier, Haydee , Rossi, Joanna , Sharpe, Richard E. , Destounis, Stamatia V. , Eby, Peter R.

Mayo Clinic

Journal of Breast Imaging | July 26, 2025 | Volume: 7 | Issue: 6 | Pages: 718-728

10.1093/jbi/wbaf048 | PMID 41183368 Get It

Abstract The initial method of detection (MOD) refers to the first imaging examination, physical symptom, or clinical sign that prompts further investigation and ultimately leads to a new breast cancer diagnosis. The MOD is assigned at the patient level and falls into 1 of 3 categories: screening in asymptomatic patients, detection by patients or health care providers, or neither of the above. The MOD should be assigned prospectively by the radiologist when interpreting an examination with a final BI-RADS category of 4 or 5, before image-guided biopsy and breast cancer diagnosis. The MOD is not assigned to examinations classified as BI-RADS category 0, 1, 2, 3, or 6, nor is it assigned in the setting of an active breast cancer diagnosis. This Clinical Practice article addresses frequently asked questions and challenging clinical scenarios compiled by the American College of Radiology’s Screening and Emerging Technology Committee to guide consistent MOD assignment. For example, if a patient presents with a lump but is ultimately found to have a suspicious finding requiring biopsy in the contralateral breast, the MOD should reflect the reason for presentation, the patient-detected symptom (Pat), even if the cancer itself is asymptomatic. By increasing awareness of MOD and standardizing MOD reporting practices, radiologists can contribute to improved data collection. While MOD is not currently tracked in U.S. cancer registries, its systematic collection may offer valuable insights into screening effectiveness, technology performance, and disparities in cancer detection. Standardized MOD reporting has the potential to strengthen early detection efforts and improve outcomes across diverse clinical settings.
Diagnosis and Management of Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline
Jones, Barbara , Soni, Nilam J. , Sullivan, Liam R, Musher, Daniel M., Erstad, Brian L. , Pickens, Chiagozie I. , Metlay, Joshua P. , Cao, Bin , Gendlina, Inessa , Hojat, Leila S , Laguio‐Vila, Maryrose , Liang, Stephen Y., Waterer, Grant , Paine, Marilynn, Wilson, Kevin R. , Jones, Barbara E , Ramirez, Julio A , Oren, Eyal , Soni, Nilam J , Sullivan, Liam R , Restrepo, Marcos I , Musher, Daniel M , Erstad, Brian L , Pickens, Chiagozie , Vaughn, Valerie M , Helgeson, Scott A , Crothers, Kristina , Metlay, Joshua P , Bissell Turpin, Brittany D , Cao, Bin , Chalmers, James D , Dela Cruz, Charles S , Hojat, Leila S , Laguio-Vila, Maryrose , Liang, Stephen Y , Waterer, Grant W , Wilson, Kevin , Ramírez, Julio A. , Oren, Eyal , Sullivan, Liam R, Vaughn, Valerie M. , Helgeson, Scott A. , Crothers, Kristina , Bissell, Brittany D. , Chalmers, James D. , Liang, Stephen Y. , Hawkins, Conall

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1164/rccm.202507-1692st | PMID 40679934 Get It

Abstract Background: Understanding of the diagnosis and treatment of adults with community-acquired pneumonia (CAP) has evolved thanks to new evidence, experience, and emerging technologies. This document updates evidence-based clinical practice guidelines on four key questions for the diagnosis and management of adult patients with CAP. Methods: A multidisciplinary panel integrated systematic reviews of comparative evidence with other relevant research and clinical experience, then applied Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology to produce recommendations using the Evidence to Decision Framework. Results: The panel formulated clinical recommendations that address questions related to CAP, including lung ultrasound for diagnosis, empiric antibacterial therapy if a test for a respiratory virus is positive, antibiotic duration, and the use of systemic corticosteroids. Conclusions: The panel formulated and provided the rationale for recommendations on selected diagnostic and treatment strategies for adult patients with CAP.
Editorial Comment
Linder, Brian J. , Linder, Brian J

Mayo Clinic

Journal of Urology | July 18, 2025 | Volume: 214 | Issue: 4 | Pages: 352-353

10.1097/ju.0000000000004672 | PMID 40679048 Get It

Clinical evaluation of adults undergoing elective surgery utilizing intraoperative incisional wound irrigation (CLEAN Wound): protocol for a randomised controlled trial
Roke, Rachel , Lillie, Erin , Daneman, Nick , Mason, Stephanie, Jiang, Yidi , Shiroky, Jonah , Puran, Sudarshani, Smith, David E. , Khalil, Jad Abou, Kayssi, Ahmed , Pinchuk, Brian, Apte, Sameer , Lamb, Tyler , Ma, Grace , Vogt, Kelly, Leslie, Kenneth , Mutabdzic, Dorotea, Gómez, David , Ladha, Karim S. , Bennett, Sean, Ullah, Shahnoor M, Holland, Jessica, Smith, Andrew J., Calderone, Michael, Herriott, Judith, Voltan, Ed, Sloan, B., Mazer, C. David , Kennedy, Erin, Aarts, Mary-Anne, Karanicolas, Paul J. , Kayssi, Ahmed , Apte, Sameer S , Lamb, Tyler , Delisle, Megan , Muaddi, Hala , Fergusson, Dean A , Marshall, John C. , Karanicolas, Paul Jack , Tomlinson, George , Serrano, Pablo E , Vogt, Kelly, Tsang, Melanie E. , Ullah, Shahnoor M, Nathens, Avery B.

Mayo Clinic

BMJ Open | July 17, 2025 | Volume: 15 | Issue: 7 | Pages: e104375

10.1136/bmjopen-2025-104375 | PMID 40675632 Get It

Introduction In moderate to high-risk surgical procedures, 15–25% of patients develop a postoperative surgical site infection. Intraoperative incisional wound irrigation has the potential to reduce surgical site infections, and additional randomised controlled trials are required to provide evidence of effectiveness. Methods and analysis This protocol describes a pragmatic, adaptive, participant and adjudicator-blinded trial at 13 sites in Canada in up to 2500 participants. Participants planned for surgery with an abdominal or groin incision, who are eligible and provide verbal consent through an integrated consent model, are randomised to receive intraoperative incisional wound irrigation with povidone-iodine, saline or no irrigation. The primary outcome is surgical site infection within 30 days postoperatively. Secondary outcomes include quality of life measured 30 days postoperatively and morbidity, mortality and healthcare utilisation within 90 days postoperatively. Ethics and dissemination This trial has been approved by the research ethics board at the participating centres and stopped enrolling participants on May 23, 2025. All participants will provide verbal consent. Results will be disseminated via presentation at conferences, publication and posted on clinicaltrials.gov. Trial registration number The study is registered with http://clinicaltrial.gov ( NCT04548661 ; 14 September 2020).
Midterm Outcomes in a Pooled Cohort of Harmony Transcatheter Pulmonary Valve Recipients
Morray, Brian H. , Gillespie, Matthew J. , Cheatham, John P. , Salavitabar, Arash , Peng, Lynn F., Jones, Thomas K. , Levi, Daniel S. , Gray, Robert G. , Asnes, Jeremy D. , Cabalka, Allison K. , Fujimoto, Kazuto , Qureshi, Athar M. , Bergersen, Lisa, Haugan, Daniel, McElhinney, Doff B. , Asnes, Jeremy D , Benson, Lee N. , McElhinney, Doff B , Jones, Thomas K , Morray, Brian H , Cabalka, Allison , Bergersen, Lisa

Mayo Clinic

Circulation: Cardiovascular Interventions | July 16, 2025 | Volume: 18 | Issue: 9 | Pages: No page available

10.1161/circinterventions.125.015196 | PMID 40665900 Get It

BACKGROUND: The Harmony transcatheter pulmonary valve (TPV) is designed to treat severe pulmonary regurgitation in the native or surgically repaired right ventricular (RV) outflow tract. Early outcomes after TPV replacement with the Harmony valve have been positive, but longer-term data are limited. METHODS: The study included patients who received a commercially available TPV22 or TPV25 device as part of the nonrandomized, prospective Native Outflow Tract Early Feasibility Study, Harmony Pivotal Trial, and Continued Access Study. Patients completed at least 3 years of follow-up, and outcomes to 5 years were reported when available. RESULTS: Eighty-nine patients were catheterized, and 86 were successfully implanted with a Harmony TPV. Median duration of follow-up was 5 (range 0–6) years in the TPV22 group and 3 (1–4) years in the TPV25 group. At 3 years, all patients with a TPV22 and 96% of those with a TPV25 had ≤mild pulmonary regurgitation. By magnetic resonance imaging, significant improvements from preimplant to 2 years were observed in RV end-diastolic volume index, RV to left ventricular end-diastolic volume ratio, and effective RV stroke volume (all P <0.001). SF-36 quality-of-life scores improved after Harmony implantation and were sustained over 3 years. Early cases of ventricular tachycardia resolved, and there were no new arrhythmias. Adverse events up to 5 years included 3 deaths unrelated to the device or procedure, 2 cases of endocarditis that were treated (1 medically, 1 transcatheter debulking of a vegetation) and resolved, 6 patients with RV outflow tract obstruction or thrombosis resulting in valve-in valve procedures, and 1 major stent fracture resulting in surgical explant. CONCLUSIONS: At 3 to 5 years, Harmony TPV replacement resulted in sustained valve competence, beneficial cardiac remodeling, and improved quality of life. Continued monitoring is needed to assess long-term outcomes and valve performance. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01762124; NCT02979587.
White matter stimulation with single electrical pulses modulates neuronal activity in visual cortex
Valencia, Gabriela Ojeda , Kapeller, Christoph , Shu, Yunhong , Miller, Kai J. , Hermes, Dora, Huang, Harvey , Kay, Kendrick , Gregg, Nicholas M. , Lundstrom, Brian N. , In, Myung‐Ho , Huston, John , Worrell, Gregory A. , Hermes, Dora

Mayo Clinic

Journal of Vision | July 15, 2025 | Volume: 25 | Issue: 9 | Pages: 2264

10.1167/jov.25.9.2264 Get It

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Brooks, Taylor , Zabor, Emily C. , Bedelu, Yohanna B., Yang, Xi , Karimi, Yasmin , Nedved, Adrienne, Wang, Yucai , Dave, Nikita, Baron, Margaret Kelsey , Trotier, Daniel, Miller, Jordan A. , Reinert, Catherine, Schwarz, Tenley, Salafian, Kiarash , Ayers, Emily C. , McKenna, Marshall, Tiger, Yun Kyoung , Sears-Smith, Megan , Peterson, Chelsea , Khan, Cyrus, Bliven, Sean Patrick , Narkhede, Mayur , Gibson, Alyssa, Munoz, Javier, Smith, Stephen D. , Hernandez‐Ilizaliturri, Francisco J. , Chinyengetere, Fadzai, Davé, Sandeep S. , Abdel-Razeq, Nayef , Hill, Brian T. , Brooks, Taylor R , Karimi, Yasmin H , Baron, Kelsey , Trotier, Daniel C , Pophali, Priyanka , Grover, Natalie S , Major, Ajay , Salafian, Kiarash , Ayers, Emily C , Brody, Joshua D , Sears-Smith, Megan , Peterson, Chelsea , Bliven, Sean P , Garza-Morales, Rodolfo , Ho, Carrie , Smith, Stephen D , Niu, Alex , Moustafa, Muhamad Alhaj , Wang, Yucai , Landsburg, Daniel J. , Hu, Boyu , Pophali, Priyanka A. , Grover, Natalie S. , Major, Ajay , Patel, Krish , Sundaram, Suchitra , Brody, Joshua , Ghosh, Nilanjan , Kline, Justin Paul , Munoz, Javier, Garza-Morales, Rodolfo , Niu, Alex , Moustafa, Muhamad Alhaj , Caimi, Paolo F.

Mayo Clinic

Blood | July 15, 2025 | Volume: 146 | Issue: 18 | Pages: 2177-2188

10.1182/blood.2025029117 | PMID 40663785 Get It

Abstract Epcoritamab and glofitamab are CD20-directed bispecific antibodies (BsAbs) approved in the United States for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Limited data exist for patients treated outside of trials. Patients with R/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collected from 21 United States institutions. Among 245 patients, 156 received epcoritamab and 89 received glofitamab, 113 were refractory to front-line therapy, 40 had MYC and BCL2 and/or BCL6 rearrangements, 147 received prior chimeric antigen receptor T-cell therapy, and 174 patients would have been ineligible for registrational trials. The overall response rate (ORR) for epcoritamab and glofitamab was 51% (23% complete response, [CR]) and 53% (30% CR), respectively. Median progression-free survival (PFS) was 2.6 months (95% confidence interval [CI], 2.0-3.8 months), and median overall survival (OS) was 7.8 months (95% CI, 6.2-11.0 months). The 6-month PFS was 36% (95% CI, 30-44) and the 6-month OS was 60% (95% CI, 54-67). Both trial ineligibility and undetectable CD20 pre-BsAbs portended shorter PFS and OS. Of 17 individuals with paired biopsies, 15 (88.2%) lost CD20 expression after BsAbs with a median time to progression of 3.7 months. This analysis including patients with R/R DLBCL shows the ORR to CD3/CD20 BsAbs was comparable to pivotal trials, although PFS and OS were lower. Baseline undetectable levels of CD20 were associated with poor outcomes. These results demonstrate the activity of BsAbs in R/R DLBCL, and underscore the importance of target antigen expression.
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
Chen, Charles D., Jack, Clifford R. , Koeppe, Robert, Hornbeck, Russ C. , Koudelis, Deborah, Keefe, Sarah , Aggarwal, Neelum T. , Bird, Thomas D. , Black, Sandra E., Chhatwal, Jasmeer P. , Day, Gregory S. , Farlow, Martin R. , Gauthier, Serge , Honig, Lawrence S., Xiong, Chengjie , Masellis, Mario, Méndez, Patricio Chrem, Ringman, John M. , Snider, B. Joy, Salloway, Stephen, Dyck, Christopher H. van , Klein, Gregory , Clifford, David B. , Hassenstab, Jason , Mills, Susan L., Perrin, Richard J., Supnet, Charlene , Wang, Guoqiao , Xiong, Chengjie , Team, for the DIAN‐TU Study, Jack, Clifford R , Day, Gregory S , Xiong, Chengjie , Chen, Charles D , Hassenstab, Jason , Supnet-Bell, Charlene , McCullough, Austin , Gordon, Brian A. , Joseph‐Mathurin, Nelly , McKay, Nicole S. , Hobbs, Diana A. , Flores, Shaney , Allegri, Ricardo , Berman, Sarah , Black, Sandra E. , Brooks, William S. , Fox, Nick C. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jucker, Mathias , Masters, Colin L. , Schofield, Peter R. , Shimada, Hiroyuki , Suzuki, Kazushi , Cruchaga, Carlos , Li, Yan , McDade, Eric , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Team, for the DIAN‐TU Study

Mayo Clinic

Alzheimer's & Dementia | July 15, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70347 | PMID 40660741 Get It

Abstract INTRODUCTION Monoclonal anti‐amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD). METHODS In the DIAN‐TU‐001 trial, 92 carriers received gantenerumab or placebo and underwent serial neuroimaging assessments including [ 11 C]‐Pittsburgh compound‐B (PiB) positron emission tomography (PET), [ 18 F]‐fluoro‐2‐deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI). RESULTS Gantenerumab significantly reduced PiB‐PET uptake overall and in most regions and showed no changes in FDG‐PET or MRI measures. Drug effects were associated with baseline PiB‐PET uptake, and the largest effects occurred in medial regions. DISCUSSION Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB‐PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design. Highlights Gantenerumab unevenly decreased Aβ burden as measured by PiB‐PET across brain regions. The strongest decrease in PiB‐PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG‐PET metabolism or MRI volumetrics after 4 years.